<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04612465</url>
  </required_header>
  <id_info>
    <org_study_id>ANTG-ASC-301</org_study_id>
    <nct_id>NCT04612465</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate Efficacy and Safety of ASC and Fibringlue or Fibringlue in Patients With Crohn's Fistula</brief_title>
  <official_title>Phase 3 Clinical Study to Evaluate Efficacy and Safety of ASC(Autologous Adipose-derived Stem Cells) and Fibringlue or Fibringlue in Patients With Crohn's Fistula.: A Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anterogen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anterogen Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III study to evaluate the efficacy and safety of ASC(Autologous&#xD;
      Adipose-derived Stem Cells) and Fibringlue or Fibringlue in Patients With Crohn's Fistula.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental: ASC(Autologous Adipose-derived Stem Cells) and Fibringlue, Comparator:&#xD;
      Fibringlue, Study type: Interventional, Study design: Randomized&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who are completely blocked fistula</measure>
    <time_frame>In the 8th week after 1st injection</time_frame>
    <description>complete blockage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are completely blocked fistula</measure>
    <time_frame>During 12 months after injection</time_frame>
    <description>complete blockage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are more than 50% blocked fistula</measure>
    <time_frame>During 12 months after injection</time_frame>
    <description>50% blockage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of evaluation about Investigator satisfaction using questionnaire</measure>
    <time_frame>In the 8th week, 6th month and 12th month after final injection</time_frame>
    <description>Score of evaluation about Investigator satisfaction range from 1 to 5. The lower this score, it means that the higher investigator's satisfaction with treatment effect of investigational product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are confirmed maintenance of fistula blockage by radiology test</measure>
    <time_frame>Between 6th month and 12th month after final injection</time_frame>
    <description>Radiology test is performed to subjects who are completely blocked fistula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual improvement effect of perianal fistula wound through photography of it</measure>
    <time_frame>Immediately before and after the injection(intervention) and during 12 months after injection(intervention)</time_frame>
    <description>Visual improvement effect of perianal fistula wound is evaluated by photograph of perianal fistula wound before and after the injection(intervention).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Crohn's Fistula</condition>
  <arm_group>
    <arm_group_label>ASC (test arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Autologous Adipose-derived Mesenchymal Stem Cells)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fibringlue</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ASC</intervention_name>
    <description>Injection of ASC(Autologous Adipose-derived Mesenchymal Stem Cells) to Crohn's Fistula.&#xD;
The ASC injection dose is about 1x10^7 cells of ASC per 1cm^2 of the surface area of the fistula, and the additional injection dose is 1.5 times the initial injection dose. and up to 30% of the ASC injection dose is administered in combination with Fibringlu.</description>
    <arm_group_label>ASC (test arm)</arm_group_label>
    <other_name>(Autologous Adipose-derived Mesenchymal Stem Cells)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fibringlue</intervention_name>
    <description>Injection of Fibringlue to Crohn's Fistula. The Fibringlu injection dose is given the size of the fistula that is fill the entire fistula, and the additional injection dose is the same.</description>
    <arm_group_label>Fibringlue</arm_group_label>
    <other_name>standard control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient who has obtained the consent of their legal representative if they are over 18&#xD;
             years of age and under 20 years of age.&#xD;
&#xD;
          2. Patient is diagnosed with Crohn's disease.&#xD;
&#xD;
          3. Patient who has one or more Crohn's fistulas .&#xD;
&#xD;
          4. In the case of women of childbearing potential, patient who is negative for beta-HCG&#xD;
             pregnancy tests at the screening visit.&#xD;
&#xD;
          5. Patient is able to give written informed consent prior to study start and willing to&#xD;
             comply with the study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient who participated in other clinical trials within 30 days prior to the start of&#xD;
             this clinical trial, or who has not passed a period equal to five times of the&#xD;
             half-life of the drug dosed in other clinical trials.&#xD;
&#xD;
          2. Patient with a medical history or family history of Variant Creutzfeld Jakob Disease&#xD;
             or related to this disease.&#xD;
&#xD;
          3. Patient who is sensitive to anesthetic drugs or bovine-derived materials.&#xD;
&#xD;
          4. Patient with autoimmune disease except for Crohn's disease.&#xD;
&#xD;
          5. Patient with infectious diseases such as HBV, HCV and HIV.&#xD;
&#xD;
          6. Patient with signs of Septicemia.&#xD;
&#xD;
          7. Patient with Active Tuberculosis.(Including patient with Anal Tuberculosis)&#xD;
&#xD;
          8. Pregnant or breast-feeding.&#xD;
&#xD;
          9. . Is unwilling to use an acceptable method of birth control during the whole study.&#xD;
&#xD;
         10. Patient with Inflammatory Bowel disease except for Crohn's disease.&#xD;
&#xD;
         11. Patient who is sensitive to Fibringlue.&#xD;
&#xD;
         12. Patient with a clinically relevant history of alcohol or drugs abuse, habitual&#xD;
             smoking.&#xD;
&#xD;
         13. Patient whose adipose tissue obtained by liposuction is insufficient to manufacture&#xD;
             the Investigational product at the intended dose.&#xD;
&#xD;
         14. Patient who is not able to understand the objective of the study or to comply with the&#xD;
             study requirements.&#xD;
&#xD;
         15. Patient who is considered by the investigator to have a significant disease which&#xD;
             might impact the study.&#xD;
&#xD;
         16. Patient who is considered not suitable for the study by investigator.&#xD;
&#xD;
         17. Patient who is Active Crohn's disease with CDAI 450 or higher.&#xD;
&#xD;
         18. Patient with medical history of surgery for malignant cancer in the past 5&#xD;
             years.(Except for carcinoma in situ)&#xD;
&#xD;
         19. Patient who exceeds 2 cm in the longest diameter of fistula.&#xD;
&#xD;
         20. Patient who dosed anti-TNF formulations such as infliximab, adalimumab, certolizumab&#xD;
             within 3 months prior to injection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KyuJoo Park, MD. Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ChangSik Yu, MD. Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>YongBeom Cho, MD. Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KyuJoo Park, MD. Ph D</last_name>
    <phone>+82-02-2072-2901</phone>
    <email>kjparkmd@plaza.snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul Natinoal Univetsity Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KyuJoo Park, MD. Ph D</last_name>
      <phone>+82-02-2072-2901</phone>
      <email>kjparkmd@plaza.snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ChangSik Yu, MD. Ph D</last_name>
      <phone>+82-02-3010-3494</phone>
      <email>csyu@amc.seoul.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YongBeom Cho, MD. Ph D</last_name>
      <email>yongbeom.cho@samsung.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

